The Health Disparities Advisory Group is focused on developing resources related to data and formulary and utilization management solutions that can close the gap on disparities in medication use. This advisory group is active from March 2022-February 2023.
Meeting Proceedings & Findings
The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
Video proceedings from the Partnership Forum "Addressing Evidence Gaps in the Expedited Programs Payer Perspectives."
Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.
Proceedings from the AMCP Partnership Forum on High-Investment Medications.
Proceedings from the AMCP Partnership Forum on High-Investment Medications.
Partnership Forum: This Partnership Forum identified opportunities to improve how value assessments are developed and applied to formulary decision-making and provide strategies and guidance on best practices to equip managed care pharmacists and other professionals when applying these tools to assess value and optimize patient care.
Partnership Forum: This forum identified challenges and payer needs related to the evidence for digital therapeutics. The forum explored the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.
Proceedings are now available.
AMCP webinar that reviewed proceedings from this Partnership Forum.
AMCP webinar that reviewed proceedings from this Partnership Forum.
Immunoglobulin (IG) derived from the plasma of donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders. To understand the appropriate and cost effective use of immunoglobulin, AMCP convened an expert panel of managed care stakeholders.